The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm
Abstract
Purpose: Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both chemotherapy and radiotherapy. We conducted a pilot phase II study of a new combined-modality paradigm of targeted therapy (cetuximab) with chemoradiotherapy. Patients and Methods: Eligible patients had stage III or IV, M0, squamous cell head and neck cancer. Treatment included concomitant boost radiotherapy (1.8 Gy/d weeks 1 to 6; boost: 1.6 Gy 4 to 6 hours later weeks 5 to 6; 70 Gy total to gross disease), cisplatin (100 mg/m 2 intravenously weeks 1 and 4), and cetuximab (400 mg/m 2 intravenously week 1, followed by 250 mg/m 2 weeks 2 to 10). Results: Twenty-two patients were enrolled (median age, 57 years; range, 41 to 72 years; median Karnofsky status, 90%; range, 70% to 90%; oropharynx primary tumor, 59% of patients; T4, 36%; N2/3, 77%; stage IV disease, 86%). One patient did not receive study treatment because of an ineligible diagnosis. The severity of expected, acute toxicities was typical of concurrent cisplatin and radiotherapy alone. Grade 3 or 4 cetuximab-related toxicities included acne-like rash (10%) and hypersensitivity (5%). However, the study was closed for significant adverse events, including two deaths (one pneumonia and one unknown cause), one myocardial infarction, one bacteremia, and one atrial fibrillation. With a median follow-up of 52 months, the 3-year overall survival rate is 76%, the 3-year progression-free survival rate is 56%, and the 3-year locoregional control rate is 71%. Conclusion: This regimen is not currently recommended outside of the clinical trial setting. Further investigation of its safety profile is needed. However, preliminary efficacy is encouraging, and further development of this targeted combined-modality paradigm is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
(1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242402 · Cited by 2,733
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., & Ang, K. K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00663-5 · Cited by 1,357
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Calais, G., Alfonsi, M., Bardet, E., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., Oudinot, P., & Bertrand, P. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2081 · Cited by 1,060
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationWendt, T. G., Grabenbauer, G. G., Rödel, C. M., Thiel, H. J., Aydin, H., Rohloff, R., Wustrow, T. P., Iro, H., Popella, C., & Schalhorn, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1318 · Cited by 634
High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
Hayes, D. M., Cvitkovic, E., Golbey, R. B., Scheiner, E., Helson, L., & Krakoff, I. H. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j · Cited by 626
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., Petersen, S. H., Yamakawa, M., Ang, K. K., Mendelsohn, J. M., & Fan, Z. (2000) · PubMed · Cited by 537
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Jeremic, B., Shibamoto, Y., Milicic, B., Nikolic, N., Dagovic, A., Aleksandrovic, J., Vaskovic, Z., & Tadic, L. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1458 · Cited by 473
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.
Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F., & Milano, G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1873 · Cited by 415
Grandis, J. R., Melhem, M. F., Barnes, E. L., & Tweardy, D. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960915)78:6<1284::aid-cncr17>3.0.co;2-x · Cited by 369
Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P. G. Y., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. N., et al. (2001) · PubMed · Cited by 322
Self-citationFan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Santini, J., Formento, J., Francoual, M., Milano, G., Schneider, M., Dassonville, O., & Demard, F. (1991) · Head & Neck · doi:10.1002/hed.2880130209 · Cited by 254
ANG, K. K., Peters, L. J., Weber, R. S., Maor, M. H., Morrison, W. H., Wendt, C. D., & Brown, B. W. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90341-g · Cited by 232
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Cohen, R. B., Raben, D., Jones, C. U., Kies, M. S., Baselga, J., & Ang, K. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.5507 · Cited by 219
Epidermal Growth Factor Receptor Family and Chemosensitization
Mendelsohn, J., & Fan, Z. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.5.341 · Cited by 171
Saleh, M. N., Raisch, K. P., Stackhouse, M. A., Grizzle, W. E., Bonner, J. A., Mayo, M. S., Kim, H., Meredith, R. F., Wheeler, R. H., & Buchsbaum, D. J. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.451 · Cited by 164
Grandis, J. R., Tweardy, D. J., & Melhem, M. F. (1998) · PubMed · Cited by 120
Miyaguchi, M., Olofsson, J. S., & Hellquist, H. B. (2009) · Clinical Otolaryngology · doi:10.1111/j.1365-2273.1991.tb02094.x · Cited by 50
Miyaguchi, M., Olofsson, J. S., & Hellquist, H. B. (1991) · Clinical Otolaryngology · doi:10.1111/j.1365-2273.1991.tb01041.x · Cited by 43
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5633 · Cited by 838
Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment
Pai, S. I., & Westra, W. H. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092158 · Cited by 508
Nguyen-Tan, P. F., Zhang, Q., Ang, K. K., Weber, R. S., Rosenthal, D. I., Soulieres, D., Kim, H., Silverman, C., Raben, A., Galloway, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3925 · Cited by 475
Qian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
Metadata
- Authors
- Pfister, D. G., Su, Y. B., Kraus, D. H., Wolden, S. L., Lis, E., Aliff, T. B., Zahalsky, A. J., Lake, S., Needle, M. N., Shaha, A. R., Shah, J. P., & Zelefsky, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-03-01
- Volume
- 24
- Issue
- 7
- Pages
- 1072-1078
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115416676
- Cited by
- 297
- References
- 34
- FWCI
- 40.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.